Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05904665

Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer

Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to rise. Patients who receive treatment in the early stage (stage I) have a 5-year survival rate of approximately 90%. However, for high-risk stage II and III colorectal cancer patients, the 5-year survival rate is only 40%-70%, and almost half of the patients experience postoperative recurrence and metastasis.

Circulating tumor DNA (ctDNA) is a small fraction of total cell-free DNA (cfDNA) in peripheral blood circulation, carrying tumor-specific genetic and epigenetic information. It can usually be detected in the serum or plasma of tumor patients in peripheral blood. Studies have shown that methylation detection of plasma ctDNA can be used for predicting the efficacy and prognosis of tumor postoperatively, as well as for dynamic monitoring.

Current methods for monitoring CRC recurrence include testing for carcinoembryonic antigen (CEA) in blood and periodic computed tomography (CT) scans. However, due to the low sensitivity of CEA and the radiation and cost limitations of CT examination, the disease status of postoperative CRC patients cannot be well-monitored.

ctDNA is a promising biomarker for monitoring the recurrence and metastasis of CRC. Research results have shown that ctDNA can be detected in nearly all subjects before surgery, and the changes in ctDNA levels are related to the extent of surgical resection. The detection of ctDNA after surgery generally indicates recurrence within one year. ctDNA may be a more reliable and sensitive indicator than the current standard biomarker CEA, providing a window for early intervention.

This multicenter, prospective, and randomized controlled cohort study uses a single-tube methylation-specific quantitative PCR (mqMSP) detection, which detects 10 different methylation markers and can quantitatively analyze plasma samples containing tumor DNA as low as 0.01%. This study will use the ctDNA methylation detection technology to conduct quantitative detection of ctDNA methylation in the plasma of enrolled patients, hoping to predict the recurrence and metastasis risk of patients at an earlier stage through ctDNA changes, and to explore the value of ctDNA detection in guiding postoperative follow-up for non-metastatic CRC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-metastatic Colorectal Cancer Circulating Tumor DNA Methylation

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old, regardless of gender;
  • Personal status (PS) score as over 80 or Eastern Cooperative Oncology Group (ECOG) score as 0 ~ 2;
  • Preoperative imaging examinations reveal no definite distant metastatic lesions, and postoperative pTNM staging confirms patients with stage I to III colorectal cancer;
  • Radical operation performed ;
  • With expected survival of more than 12 months;
  • The subjects (or their legal representative / Guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.

Exclusion criteria

  • Blood transfusion performed during operation or within 2 weeks before operation;
  • Incomplete baseline samples, including preoperative plasma samples;
  • Two consecutive test points missing or three plasma samples missing in total before a positive ctDNA time point;
  • Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;
  • Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;
  • Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;
  • Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;
  • Significant impairment of important organ function;
  • Other conditions in which the investigator believes that the patient should not participate in this trial.

Treatment and study plan

ctDNA methylation dynamic monitoring

Diagnostic Test

ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.

Primary outcomes

  1. Secondary curative-intent rate

    Time frame: Up to 24 months

    This study primarily evaluates whether ctDNA-informed surveillance after surgery increases the proportion of patients with CRC recurrence who receive curative-intent or metastasis-directed therapy, compared to the standard follow-up protocol within 2 years of initial surgery.

Secondary outcomes

  1. TTCR

    Time frame: Up to 60 months

    To exam whether ctDNA-guided surveillance leads to a reduced time to clinical recurrence (TTCR) compared to standard surveillance.

  2. DFS

    Time frame: Up to 60 months

    To investigate ctDNA-based disease-free survival (ctDNA-DFS), CT-based disease-free survival (CT-DFS), and the difference between ctDNA-DFS and CT-DFS (△-DFS).

  3. Sensitivity of postoperative ctDNA monitoring for detecting recurrence

    Time frame: Up to 60 months

    To investigate sensitivity of postoperative ctDNA monitoring for detecting recurrence (Sensitivity=Number of ctDNA-positive patients confirmed with recurrence by imaging/Total number of patients confirmed with recurrence by imaging).

  4. Specificity of postoperative ctDNA monitoring for detecting recurrence

    Time frame: Up to 60 months

    To investigate specificity of postoperative ctDNA monitoring for detecting recurrence (Specificity= Number of ctDNA-negative patients confirmed without recurrence by imaging /Total number of patients confirmed without recurrence by imaging).

  5. OS

    Time frame: Up to 60 months

    To exam whether 3- and 5-year overall survival (OS) with ctDNA-guided surveillance is comparable to that achieved with standard CT-based monitoring.

  6. Patient-reported outcomes (quality of life)

    Time frame: Up to 60 months

    To assess patient-reported outcomes-quality of life (EORTC QLQ-C30)-in those receiving ctDNA-guided versus standard surveillance.

  7. Patient-reported outcomes (fear of cancer recurrence)

    Time frame: Up to 60 months

    To assess patient-reported outcomes-fear of cancer recurrence (FCRI)-in those receiving ctDNA-guided versus standard surveillance.

  8. Patient-reported outcomes (cancer-related distress)

    Time frame: Up to 60 months

    To assess patient-reported outcomes-cancer-related distress (IES-C)-in those receiving ctDNA-guided versus standard surveillance.

  9. Patient-reported outcomes [emotional distress (PHQ-9 scales)]

    Time frame: Up to 60 months

    To assess patient-reported outcomes-emotional distress (PHQ-9 scales)-in those receiving ctDNA-guided versus standard surveillance.

  10. Patient-reported outcomes [emotional distress (GAD-7 scales)]

    Time frame: Up to 60 months

    To assess patient-reported outcomes-emotional distress (GAD-7 scales)-in those receiving ctDNA-guided versus standard surveillance.

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer: a Multicenter, Prospective, Randomized Controlled Cohort Study (FIND Trial)

Important dates

Study start
2023
Primary completion
2025
Study completion
2028
First posted
Jun 15, 2023
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.